Detailed Information

Cited 4 time in webofscience Cited 5 time in scopus
Metadata Downloads

Efficacy and Tolerability of Amlodipine Camsylate/Losartan 5/100-mg Versus Losartan/Hydrochlorothiazide 100/12.5-mg Fixed-Dose Combination in Hypertensive Patients Nonresponsive to Losartan 100-mg Monotherapy

Authors
Suh, Soon YongAhn, TaehoonBae, Jang-HoLim, Do-SunLee, Seoung UkKim, Young KwonHyon, Min SuKim, Won HoHan, Kyoo RokPark, Hoon Ki
Issue Date
Oct-2014
Publisher
ELSEVIER
Keywords
amlodipine; hypertension; losartan
Citation
CLINICAL THERAPEUTICS, v.36, no.10, pp 1402 - 1411
Pages
10
Indexed
SCI
SCIE
SCOPUS
Journal Title
CLINICAL THERAPEUTICS
Volume
36
Number
10
Start Page
1402
End Page
1411
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/8919
DOI
10.1016/j.clinthera.2014.07.003
ISSN
0149-2918
1879-114X
Abstract
Purpose: The aim of this study was to determine whether the efficacy and tolerability of amlodipine camsylate/losartan 5/100 mg/d (AML/LOS) are noninferior to those of losartan/hydrochlorothiazide 100/12.5 mg/d (LOS/HCTZ) fixed-dose combination in hypertensive patients unresponsive to losartan 100-mg/d monotherapy. Methods: Male and female patients aged >= 18 years with hypertension despite 4-week, stable treatment with losartan 100-mg/d monotherapy were eligible for inclusion in this multicenter, randomized, double-blind study. Patients were randomly assigned to receive AML/LOS or LOS/HCTZ once daily for 8 weeks. The primary end point was the change from baseline to week 8 in sitting diastolic blood pressure (Delta siDBP), and the secondary end points were the changes from baseline to 4 weeks in siDBP and sitting systolic BP (Delta siSBP) and changes from baseline to 4 and 8 weeks in BP response rate. Tolerability was evaluated by physical examination, including vital sign measurement; laboratory analysis; and ECG. Findings: Of 275 patients screened at 9 cardiovascular centers, 199 were enrolled (AML/LOS, n = 101; LOS/HCTZ, n = 98), and 183 completed the study. The demographic characteristics were similar between the 2 groups (mean age, 51.56 [9.97] years; men, 70.53%). At 8 weeks, the mean Delta siDBP values were -11.54 (7.89) and -9.05 (6.57) mm Hg in the AML/LOS and LOS/HCTZ groups, respectively (both, P < 0.0001 vs baseline). The mean difference between the 2 groups was -2.57 mm Hg, a nonsignificant difference, meaning that AML/LOS was noninferior to LOS/HCTZ with regard to the primary end point. At 8 weeks, the mean uric acid level was changed significantly from baseline in the LOS/HCTZ group (+0.41 [0.80] mg/dL; P < 0.0001) but not in the AML/LOS group (-0.12 [0.82] mg/dL), representing a significant intergroup difference (P < 0.0001). Nineteen patients each in the AML/LOS (18.81%) and LOS/HCTZ (20.00%) groups experienced >= 1 adverse event, with 4 (3.96%) and 3 (3.16%) patients, respectively, experiencing 1 or more events considered by the investigators to have been treatment related. (C) 2014 Elsevier HS Journals, Inc. All rights reserved.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Cardiology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Lim, Do Sun photo

Lim, Do Sun
Anam Hospital (Department of Cardiology, Anam Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE